Preclinical evaluation of early multi-organ toxicity induced by liposomal doxorubicin using 67Ga-citrate

Nanotoxicology. 2022 Mar;16(2):247-264. doi: 10.1080/17435390.2022.2071180. Epub 2022 May 15.

Abstract

Although liposomal doxorubicin (LPD) is widely used for cancer treatment, knowledge concerning the toxicity induced by this drug in healthy organs and tissues is limited. LPD-induced toxicity studies relative to free doxorubicin (DOX) have focused on cardiotoxicity in tumor-bearing animals. On the other hand, the results on DOX-induced cardiotoxicity depending on gender are controversial. One of the manifestations of toxicity is tissue inflammation. 67Ga-citrate has been used for decades to assess inflammation in various pathologies. In this work, the ex vivo biodistribution of 67Ga-citrate is used to evaluate induced multi-organ toxicity in healthy 10-week-old male and female CD1 mice treated for 5 weeks with LPD. Toxicity in males, determined by 67Ga-citrate, was evident only in the target organs of liposomes (spleen, liver, kidneys, and lungs); the average weight loss was 11% and mortality was 14%. In female mice, 67Ga-citrate revealed a cytotoxic effect in practically all organs, the average weight loss was 37%, and the mortality after the last dose of LPD was 66%. These results confirm the usefulness of 67Ga-citrate and the importance of stratifying by sex in the toxicological evaluation of drugs.

Keywords: 67Ga-citrate; Liposomal doxorubicin; biodistribution; multi-organ toxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic* / toxicity
  • Cardiotoxicity* / drug therapy
  • Citric Acid / toxicity
  • Doxorubicin / analogs & derivatives
  • Doxorubicin / toxicity
  • Female
  • Inflammation
  • Liposomes / pharmacology
  • Male
  • Mice
  • Polyethylene Glycols
  • Tissue Distribution
  • Weight Loss

Substances

  • Antibiotics, Antineoplastic
  • Liposomes
  • liposomal doxorubicin
  • Citric Acid
  • Polyethylene Glycols
  • Doxorubicin